A Screening of the MMV Pandemic Response Box Reveals Epetraborole as A New Potent Inhibitor against Mycobacterium abscessus

Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus

(2020) Matt D. Johansen et al.   NATURE REVIEWS MICROBIOLOGY

A mouse model of pulmonary Mycobacteroides abscessus infection

(2020) Emily C. Maggioncalda et al.   Scientific Reports

Rifamycin O, An Alternative Anti-Mycobacterium abscessus Agent

(2020) Bui Thi Bich Hanh et al.   MOLECULES

Etamycin as a Novel Mycobacterium abscessus Inhibitor

(2020) Bui Thi Bich Hanh et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Eravacycline: A Review in Complicated Intra-Abdominal Infections

(2019) Lesley J. Scott   DRUGS

Biofilm-associated Mycobacterium abscessus cells have altered antibiotic tolerance and surface glycolipids in Artificial Cystic Fibrosis Sputum Media.

(2019) Augusto Cesar Hunt-Serracin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

(2019) Amit Kaushik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection

(2019) Lea Bentur et al.   Journal of Cystic Fibrosis

Extremely low hit rate in a diverse chemical drug screen targeting Mycobacterium abscessus

(2019) Jakob J Malin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

THP-1 and Dictyostelium Infection Models for Screening and Characterization of Anti-Mycobacterium abscessus Hit Compounds

(2019) Adrian Richter et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Thiostrepton: A Novel Therapeutic Drug Candidate for Mycobacterium abscessus Infection

(2019) Tae Ho Kim et al.   MOLECULES

In Vitro and In Vivo Activities of DS86760016, a Novel Leucyl-tRNA Synthetase Inhibitor for Gram-Negative Pathogens

(2018) Kedar P. Purnapatre et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of the intracellular activity of drugs against Mycobacterium abscessus using a THP-1 macrophage model

(2018) Carmen Amelia Molina-Torres et al.   JOURNAL OF MICROBIOLOGICAL METHODS

Pathogen Box screening for hit identification against Mycobacterium abscessus

(2018) Jinsun Jeong et al.   PLoS One

Glycopeptidolipids, a Double-Edged Sword of the Mycobacterium abscessus Complex

(2018) Ana Victoria Gutiérrez et al.   Frontiers in Microbiology

The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Mycobacterium abscessus Drug Resistance

(2018) Sakshi Luthra et al.   Frontiers in Microbiology

Identification of Virulence Markers of Mycobacterium abscessus for Intracellular Replication in Phagocytes

(2018) Violaine Dubois et al.   Jove-Journal of Visualized Experiments

Novel Screen to Assess Bactericidal Activity of Compounds Against Non-replicating Mycobacterium abscessus

(2018) Bryan J. Berube et al.   Frontiers in Microbiology

The Diverse Cellular and Animal Models to Decipher the Physiopathological Traits of Mycobacterium abscessus Infection

(2017) Audrey Bernut et al.   Frontiers in Cellular and Infection Microbiology

Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates

(2017) Jian Liang Low et al.   Frontiers in Microbiology

Reporter-Based Assays for High-Throughput Drug Screening against Mycobacterium abscessus

(2017) Rashmi Gupta et al.   Frontiers in Microbiology

Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase

(2016) Andrés Palencia et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection

(2016) Beatriz E. Ferro et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fragment-Based Whole Cell Screen Delivers Hits against M. tuberculosis and Non-tuberculous Mycobacteria

(2016) Wilfried Moreira et al.   Frontiers in Microbiology

Susceptibility of Mycobacterium abscessus to Antimycobacterial Drugs in Preclinical Models

(2015) Andrés Obregón-Henao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease

(2015) Julie V. Philley et al.   CHEST

New insights into the survival mechanisms of rifampicin-resistantMycobacterium tuberculosis

(2015) Du Toit Loots   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Deciphering and Imaging Pathogenesis and Cording of Mycobacterium abscessus in Zebrafish Embryos

(2015) Audrey Bernut et al.   Jove-Journal of Visualized Experiments

In VivoAssessment of Drug Efficacy against Mycobacterium abscessus Using the Embryonic Zebrafish Test System

(2014) Audrey Bernut et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Testing Tuberculosis Drug Efficacy in a Zebrafish High-Throughput Translational Medicine Screen

(2014) Anita Ordas et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bacterial Resistance to Leucyl-tRNA Synthetase Inhibitor GSK2251052 Develops during Treatment of Complicated Urinary Tract Infections

(2014) Karen O'Dwyer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mycobacterium abscessus cording prevents phagocytosis and promotes abscess formation

(2014) A. Bernut et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens

(2013) J. A. Sutcliffe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Evaluation of Antibiotic Activity Against Mycobacterium abscessus

(2013) Isabelle Lerat et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation of the pathogenesis and treatment of Mycobacterium marinum infection in zebrafish

(2013) Kevin Takaki et al.   Nature Protocols

Approval of Novel TB Drug Celebrated--With Restraint

(2013) J. Cohen   SCIENCE

Clinical and Microbiologic Outcomes in Patients Receiving Treatment for Mycobacterium abscessus Pulmonary Disease

(2011) Julie Jarand et al.   CLINICAL INFECTIOUS DISEASES

Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae

(2011) S. Chopra et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

TMC207: the first compound of a new class of potent anti-tuberculosis drugs

(2010) Alberto Matteelli et al.   Future Microbiology